Phanes Therapeutics Expands Dosing in Spevatamig Clinical Study for Biliary Tract Cancer
Phanes Therapeutics, Inc. has announced a significant milestone in its ongoing clinical trials for spevatamig, a cutting-edge bispecific antibody targeting claudin 18.2 and CD47. The company, which focuses on advancing innovative therapies within oncology, has begun a dose expansion phase for treating biliary tract cancer (BTC). This follows successful clearance of dose-limiting toxicities at two previous dosing levels.
Spevatamig has gained traction in the field due to its first-in-class profile, previously awarded orphan drug designation by the FDA for pancreatic cancer in 2022, and Fast Track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024.
Moreover, Phanes formed a clinical collaboration with Merck to investigate the efficacy of combining spevatamig with Merck's pembrolizumab, an anti-PD-1 therapy. This partnership underscores the potential and versatility of spevatamig as a complementary treatment option.
Phanes has been at the forefront of several oncology studies involving spevatamig, including a Phase 2 trial exploring its effectiveness in first-line pancreatic ductal adenocarcinoma (PDAC) patients. As of March 2026, over 160 patients globally have been administered spevatamig, either as a standalone treatment or in conjunction with other therapies.
Furthermore, the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego will feature three presentations from Phanes on spevatamig, showcasing their research findings and the drug's progress. This highlights Phanes Therapeutics' commitment to engaging with the medical community and sharing advancements in cancer treatment.
Notably, Phanes Therapeutics utilizes proprietary technology platforms such as PACbody®, SPECpair®, and ATACCbody® to develop innovative biologics addressing pressing unmet medical needs in oncology. With ongoing Phase 2 trials involving spevatamig, peluntamig, and mavrostobart, Phanes is well-positioned in the competitive landscape of biopharmaceuticals.
The company's strategic approach to drug development not only focuses on novel mechanisms but also ensures that they are aligned with regulatory pathways, enhancing their potential for successful outcomes in clinical trials.
For those seeking further information about Phanes Therapeutics or their promising therapeutic candidates, the company provides resources on their official website. They encourage inquiries about business development and media-related topics through their contact channels.
In summary, Phanes Therapeutics is advancing its clinical studies on spevatamig, marking a notable expansion in its investigational endeavors. By focusing on innovative combinations such as chemotherapy with spevatamig, they aim to improve treatment strategies for patients battling biliary tract cancer, alongside their broader commitment to revolutionizing oncology therapeutics.
Spevatamig has gained traction in the field due to its first-in-class profile, previously awarded orphan drug designation by the FDA for pancreatic cancer in 2022, and Fast Track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024.
Moreover, Phanes formed a clinical collaboration with Merck to investigate the efficacy of combining spevatamig with Merck's pembrolizumab, an anti-PD-1 therapy. This partnership underscores the potential and versatility of spevatamig as a complementary treatment option.
Phanes has been at the forefront of several oncology studies involving spevatamig, including a Phase 2 trial exploring its effectiveness in first-line pancreatic ductal adenocarcinoma (PDAC) patients. As of March 2026, over 160 patients globally have been administered spevatamig, either as a standalone treatment or in conjunction with other therapies.
Furthermore, the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego will feature three presentations from Phanes on spevatamig, showcasing their research findings and the drug's progress. This highlights Phanes Therapeutics' commitment to engaging with the medical community and sharing advancements in cancer treatment.
Notably, Phanes Therapeutics utilizes proprietary technology platforms such as PACbody®, SPECpair®, and ATACCbody® to develop innovative biologics addressing pressing unmet medical needs in oncology. With ongoing Phase 2 trials involving spevatamig, peluntamig, and mavrostobart, Phanes is well-positioned in the competitive landscape of biopharmaceuticals.
The company's strategic approach to drug development not only focuses on novel mechanisms but also ensures that they are aligned with regulatory pathways, enhancing their potential for successful outcomes in clinical trials.
For those seeking further information about Phanes Therapeutics or their promising therapeutic candidates, the company provides resources on their official website. They encourage inquiries about business development and media-related topics through their contact channels.
In summary, Phanes Therapeutics is advancing its clinical studies on spevatamig, marking a notable expansion in its investigational endeavors. By focusing on innovative combinations such as chemotherapy with spevatamig, they aim to improve treatment strategies for patients battling biliary tract cancer, alongside their broader commitment to revolutionizing oncology therapeutics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.